Department of Food Science and Biotechnology, National Chung Hsing University, 250 Kuo-Kuang Road, Taichung, 40227, Taiwan.
Department of Food Science and Biotechnology, National Chung Hsing University, 250 Kuo-Kuang Road, Taichung, 40227, Taiwan.
Eur J Pharmacol. 2022 Sep 15;931:175222. doi: 10.1016/j.ejphar.2022.175222. Epub 2022 Aug 19.
To screen potent terpenoid compounds against allergic inflammation in vitro and in vivo, five terpenoid compounds including menthone, farnesol, oridonin, β-escin and lupeol, were first selected to compare their anti-allergic inflammation potential using mouse lung mast cells in vitro. Among five selected terpenoid compounds, just menthone treatment decreased TNF-α/IL-10 secretion ratios in lipopolysaccharide -stimulated mast cells in vitro. As a result, menthone was further chosen to treat ovalbumin (OVA)-sensitized and challenged BALB/c mice by gavage for 5 weeks. There were six groups including dietary control (DC group, 0 mg menthone/kg b.w./day), 8 (ML group), 40 (MM group) as well as 200 mg menthone/kg b.w./day (MH group) by gavage, positive control (PC group, 3 mg dexamethasone/kg b.w. by gavage before OVA challenge) and non-treatment control (NTC group, normal mice without treatment) in the experiment. Changes of inflammatory mediators, cell distribution, Th1/Th2 and pro-/anti-inflammatory cytokines secretion as well as relative gene expression amounts of six receptors related to allergic inflammation in the lungs and airways were measured. The results showed that middle menthone supplementation (40 mg menthone/kg b.w./day) in vivo decreased protein and eotaxin, but increased Th1 cytokine levels in the bronchoalveolar lavage fluid. Menthone supplementation inhibited eosinophilia, mast cell degranulation, chemokine (C-C motif) receptor 3 (CC receptor 3) and chemokine (C-X-C motif) receptor 1 (CXC receptor 1) gene expression amounts in the lungs, but restored the percentage of monocytes/macrophages. Our results suggest that menthone supplementation may alleviate allergic asthma through regulating airway allergic inflammation, protein overproduction, eosinophils infiltration, Th1/Th2 immune balance, CC receptor 3 and CXC receptor 1 gene expression amounts in the lungs but restoring the percentage of monocytes/macrophages in allergic asthmatic mice.
为了筛选体外和体内有抗过敏炎症活性的有效萜类化合物,本研究首先选择了 5 种萜类化合物(包括薄荷酮、法呢醇、冬凌草甲素、β-七叶皂苷元和羽扇豆醇),比较它们对体外小鼠肺肥大细胞的抗过敏炎症活性。在这 5 种萜类化合物中,只有薄荷酮处理能降低脂多糖刺激的肥大细胞中 TNF-α/IL-10 分泌比值。因此,进一步选择薄荷酮通过灌胃治疗卵清蛋白(OVA)致敏和激发的 BALB/c 小鼠 5 周。实验中有 6 个组,包括膳食对照(DC 组,0 mg 薄荷酮/kg b.w./天)、8 (ML 组)、40(MM 组)和 200 mg 薄荷酮/kg b.w./天(MH 组),通过灌胃给药、阳性对照(PC 组,OVA 激发前 3 mg 地塞米松/kg b.w.)和非治疗对照(NTC 组,未经治疗的正常小鼠)。测量了肺部和气道中炎症介质、细胞分布、Th1/Th2 和促炎/抗炎细胞因子分泌以及与过敏炎症相关的 6 种受体的相对基因表达量的变化。结果表明,体内中薄荷酮补充(40 mg 薄荷酮/kg b.w./天)可降低支气管肺泡灌洗液中的蛋白和嗜酸性粒细胞趋化因子,但增加 Th1 细胞因子水平。薄荷酮补充抑制嗜酸性粒细胞增多、肥大细胞脱颗粒、趋化因子(C-C 基元)受体 3(CC 受体 3)和趋化因子(C-X-C 基元)受体 1(CXC 受体 1)基因表达量,但恢复单核细胞/巨噬细胞的百分比。我们的结果表明,薄荷酮补充可能通过调节气道过敏炎症、蛋白过度产生、嗜酸性粒细胞浸润、Th1/Th2 免疫平衡、CC 受体 3 和 CXC 受体 1 基因表达量来缓解过敏性哮喘,但恢复过敏性哮喘小鼠中单核细胞/巨噬细胞的百分比。